Reuters logo
BRIEF-Oncology Venture Sweden and Eisai sign exclusive global license agreement
July 7, 2017 / 12:43 PM / 5 months ago

BRIEF-Oncology Venture Sweden and Eisai sign exclusive global license agreement

July 7 (Reuters) - ONCOLOGY VENTURE SWEDEN AB

* ONCOLOGY VENTURE AND EISAI FORGE EXCLUSIVE GLOBAL LICENSE AGREEMENT FOR CLINICAL STAGE ONCOLOGY DRUG PARP INHIBITOR E7449 / 2X-121 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below